КР159. Легочная гипертензия, в том числе хроническаятромбоэмболическая легочная гипертензия

Название	Легочная гипертензия, в том числе хроническаятромбоэмболическая легочная гипертензия
Дата	22.01.2022
Размер	1.67 Mb.
Формат файла
Имя файла	КР159.pdf
Тип	Документы #338922
страница	15 из 17

1 ... 9 10 11 12 13 14 15 16 17

Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685–713.
68. Focardi M, Cameli M, Carbone SF, et al. Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging 2015; 16: 47–52.;
69. Hellenkamp K, Unsold B, Mushemi-Blake S, et al. Echocardiographic estimation of mean pulmonary artery pressure: a comparison of different approaches to assign the likelihood of pulmonary hypertension. J Am Soc Echocardiogr 2018; 31: 89–98.
70. Kaemmerer H, Apitz C, Brockmeier K, Eicken A, Gorenﬂo M, Hager A, de Haan F, Huntgeburth M,
Kozlik-Feldmann RG, Miera O, Diller GP. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J
Cardiol. 2018; 272S:79-88.
71. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA,
Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare
GF.2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A
Report of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Circulation. 2019; 139(14):e698-e800.
72. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA,
Jenkins DP. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019 Jan 24; 53(1).
pii: 1801915.
73. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; №48:680–684.
74. Leblanc M, Leveillée F, Turcotte E. Prospective evaluation of the negative predictive value of V/Q
SPECT using99mTc-Technegas. Nucl Med Commun 2007; 28: 667–672.
75. Grüning T, Drake BE, Farrell SL, et al. Three-year clinical experience with VQ SPECT for diagnosing pulmonaryembolism: diagnostic performance. Clin Imaging 2014; 38: 831–835.
76. Meng JJ, Zhang LJ, Wang Q et al. A comparison of ventilation/perfusion single photon emission
CT and CT pulmonary angiography for diagnosis of pulmonary embolism. Zhonghua Jie He He
Hu Xi Za Zhi 2013; 36:177–181.

77. Lau EM, Bailey DL, Bailey EA, et al. Pulmonary hypertension leads to a loss of gravity dependent redistribution of regional lung perfusion: a SPECT/CT study. Heart 2014; 100: 47–53.
78. Rajaram S, Swift AJ, Telfer A, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE
Registry. Thorax 2013; 68:677–678.
79. Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging 2017; 46: 1693–1697.
80. Rajaram S, Swift AJ, Condliffe R et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax
2015; 70:382–387.
81. Tan RT, Kuzo R, Goodman LR et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998; 113:1250–1256.
82. Shen Y, Wan C, Tian P, Wu Y, Li X, Yang T, An J, Wang T, Chen L, Wen F. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine (Baltimore) 2014; 93:e256.
83. Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, Simonneau G, Musset D.
Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am J Roentgenol
2004; 183:65–70.
84. Montani D, Price LC, Dorfmuller P et al. Pulmonary veno-occlusive disease. Eur Respir J 2009;
33:189–200.
85. Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic pulmonary hypertension. Eur
Respir J 2004; 23:637–648.
86. Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J
Radiol 2008; 71:49–54.
87. Мартынюк Т. В., Наконечников С. Н., Чазова И. Е. На пути оптимизации подходов к лечению хронической тромбоэмболической легочной гипертензии. СonsiliumMedicum.
2016; №5: с.53–58.
88. Марукян Н. В., Симакова М. А., Карпова Д. В., и др. Реперфузионный отек легкого как осложнение баллонной ангиопластики легочной артерии у пациентов с хронической тромбоэмболической легочной гипертензией Флебология. 2017. Т. 11. No 4. С. 243–248.
89. Giordano J, Khung S, Duhamel A, et al. Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension
(pCTEPH): dual-energy CT experience in 31 patients. Eur Radiol 2017; 27: 1631–1639.
90. Fukui S, Ogo T, Morita Y et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014; 43:1394–1402.
91. Nawaz A, Litt HI, Stavropoulos SW et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv
Radiol 2008; 19:1582–1588.
92. Рeacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev 2013; 22:526–534.
93. Swift AJ, Rajaram S, Condliffe R et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson 2012;
14:40–50.
94. Swift AJ, Rajaram S, Hurdman J. et al. Noninvasive estimation of PA pressure, ﬂow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE
registry. JACC Cardiovasc Imaging 2013; 6: 1036–1047.
95. Симакова М. А., Рыжков А. В., Казымлы А. В. и др. Перспективы использования показателей жесткости легочной артерии для оценки прогноза пациентов с легочной артериальной гипертензией. Терапевтический архив. 2018. Т. 90. No 1. С. 86–92.
96. van Wolferen SA, Marcus JT et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28:1250–1257.
97. Peacock AJ, Crawley S, McLure L et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension – targeted therapy: the EURO-MR Study. Circ Cardiovasc Imaging 2014; 7:107–114.
98. van de Veerdonk MC, Kind T, Marcus JT et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;
58:2511–2519.
99. Ley S, Kauczor HU, Heussel CP et al. Value of contrast-enhanced MR angiography and helical CT
angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2003; 13:2365–

2371.
100. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. SwissMed Wkly 2003;
133:163–169.
101. Hoeper MM, Lee SH, Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;
48:2546–2552.
102. Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit
Care Med 2014; 190:252–257.
103. Lammi MR, Saketkoo LA, Gordon JK, Steen VD. Changes in hemodynamic classiﬁcation over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the
PHAROS cohort Pulm Circ. 2018 Apr-Jun; 8(2):2045893218757404.
104. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures
16 to 18 mm Hg: insights from the REVEAL Registry. Chest 2013; 143:185–195.
105. Abraham WT, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377:658–666.
106. Prasad A, Hastings JL, Shibata S et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart
Fail 2010; 3:617–626.
107. Fujimoto N, Borlaug BA, Lewis GD et al Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 2013;127:55–62.
108. Fox BD, Shimony A, Langleben D et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013; 42:1083–1091.
109. Robbins IM, Hemnes AR, Pugh ME et al. High prevalence of occult pulmonary venous hypertension revealed by ﬂuid challenge in pulmonary hypertension. Circ Heart Fail 2014;
7:116–122.
110. Jean-Luc Vachiéry, Ryan J. Tedford, Stephan Rosenkranz et al. Pulmonary hypertension due to left heart disease Eur Respir J. 2019 Jan 24; 53(1). pii: 1801897.
111. Borlaug BA, Nishimura RA, Sorajja P et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588–595.
112. Hager WD, Collins I, Tate JP et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J
2013; 7: 227–236.
113. Maor E, Grossman Y, Balmor RG et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail. 2015;
17(2):151–158.
114. Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, Fabel H. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535–541.
115. Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH, Lichtblau M, Nagel C, Peters K,
Rosenkranz S, Schranz D, Skowasch D, Tiede H, Weil J, Ewert R. Pulmonary hypertension:
Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference
2011. Int J Cardiol. 2011 Dec; 154 Suppl 1:S13-9.
116. Grünig, E., Benjamin, N., Krüger, U., Kaemmerer, H., Harutyunova, S., Olsson, K. M., Klose, H.
General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018 // International Journal of
Cardiology. 2018. doi:10.1016/j.ijcard.2018.08.085.
117. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel
H, Seeger W. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll
Cardiol 2000; 35(1):176–182.
118. Eyries M, Montani D, Girerd B et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65–69.
119. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB,
McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012; 141(2):354–362.
120. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P,
Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA, Barberà JA; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur. Respir. J. 2012; 40(3):
596–603.

121. Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur. Respir. J. 2012; 40(3): 604–611.
122. Medrek SK, Sahay S. Ethnicity in pulmonary arterial hypertension: possibilities for novel phenotypes in the age of personalized medicine. Chest 2018; 153(2):310–320.
123. Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR. Socioeconomic status affects pulmonary hypertension disease severity at time of ﬁrst evaluation. Pulm Circ. 2016; 6(2):191–195.
124. Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013; 187(3):303–310.
125. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, Clerson P, Cordier JF,
Simonneau G, Humbert M. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013; 72(12):1940–1946.
126. Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013; 144(1):
169–176.
127. Savarese G., Paolillo S., Costanzo P., D"Amore C., Cecere M., Losco T., Musella F., Gargiulo P.,
Marciano C., Perrone-Filardi P. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials // J. Am.
Coll. Cardiol. – 2012. – Vol. 60. – N. 13. – P. 1192–1201.
128. Казымлы А. В., Березина А. В., Рыжков А. В., Козленок А. В., Наймушин А. В., Моисеева О.
М. Кардиопульмональное тестирование как метод оценки степени тяжести пациентов с прекапиллярной легочной гипертензией // Кардиология. – 2014. – Т. 54. – № 12. – С. 22–28.
129. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratiﬁcation at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39: 4175–
4181.
130. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratiﬁcation model. Eur Respir
J 2017; 50: 1700740.
131. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889.
132. Hoeper M, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur
Respir J 2018; 51: 1702606.
133. Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension.
Psychosom Med 2004; 66:831-6.
134. Алехин А. Н., Андреева Е. В., Трифонова Е. А., Гончарова Н. С., Моисеева О. М. Социальная и психологическая адаптация пациентов с синдромом Эйзенменгера. Научные заметки института Лесгафта 2012; 91(9): 14–22.
135. Morris N.R., Kermeen F.D., Holland A.E. Exercise-based rehabilitation programmes for pulmonary hypertension. //Cochrane Database of Systematic Reviews. 2017.
doi:10.1002/14651858.cd011285.pub2.
136. Chia K. S. W., Wong P. K. K., Faux S. G. et al. The beneﬁt of exercise training in pulmonary hypertension: a clinical review. Internal Medicine Journal 2017; 47(4), 361–369.
doi:10.1111/imj.13159.
137. Ehlken N., Lichtblau1 M., Klose H., Weidenhammer J., Grünig E. et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective,
randomized, controlled trial. Eur heart J.; 37(1): 35-44. doi: 10.1093/eurheartj/ehv337.
138. Yuan P., Yuan X.T., Sun X.Y., Pudasaini B., Liu J.M., Hu Q.H. Exercise training for pulmonary hypertension: A systematic review and meta-analysis. //International journal of cardiology.
2014; 178:142–146.
139. Pandey A., Garg S., Khunger M., Garg S., Kumbhani D.J., Chin K.M. et al. Efﬁcacy and Safety of
Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. //
Circulation Heart failure. 2015; 8:1032–1043.
140. Buys R., Avila A., Cornelissen V.A. Exercise training improves physical ﬁtness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials.
BMC Pulm Med. 2015; 15:40.
141. Steppan J., Diaz-rodriguez N., Barodka V. M., et al. Focused Review of Perioperative Care of
Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. Cureus 2018 10(1): e2072. DOI 10.7759/cureus.2072.
142. Thangamathesvaran, L., Armenia, S. J., Merchant, A. M. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. // Updates in Surgery. 2018
doi:10.1007/s13304-018-0556-y.

143. Pilkington S. A., Taboada D., Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery//Anaesthesia 2015, 70, 56–70.
144. Sarkar MS, Desai PM. Pulmonary hypertension and cardiac anesthesia: Anesthesiologist"s perspective. Ann Card Anaesth 2018; 21:116–22.
145. Díaz-Gómez J.L., Ripoll J.G., Mira-Avendano I. Multidisciplinary Perioperative Management of
Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. Southern medical journal 2018. Vol.111 (11) DOI: 10.14423/SMJ.0000000000000755.
146. Легочная гипертензия. Под редакцией С. Н. Авдеева. Москва. ГЭОТАР-Медиа. 2019. – 608 с.
147. Klinger J R., Elliott G, Levine D J., Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM.,
Ryan J J., Rosenzweig EB., Sederstrom N, Steen VD., Badesch DB. Therapy for Pulmonary Arterial
Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report CHEST 2019;
155(3):565–586.
148. Fuster V., Steele P.M., Edwards W.D., Gersh B.J. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70:580–587.
149. Bjornsson J., Edwards W.D. Primary pulmonary hypertension: a histopathologic study of 80
cases. Mayo Clin Proc. 1985; 60:16–25.
150. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW et al. Effect of Warfarin
Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;
132(25):2403–2411.
151. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis
Res Ther.2012; 14(5): R213.
152. Olsson K.M., Delcroix M., Ghofrani H.A., Klose H., Claussen M., Ewert R., Opitz C.F., Vizza C.D.,
Scelsi L., Vonk-Noordegraaf A., Kaemmerer H., Gibbs J.S., Coghlan G., Pepke-Zaba J., Schulz U.,
Gorenﬂo M., Pittrow D., Hoeper M.M. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation.2014; 129:57–65.
153. Said K. Anticoagulation in pulmonary arterial hypertension: Contemporary data from
COMPERA registry. Glob Cardiol Sci Pract 2014; 2014(2): 48–52.
154. Roldan T, Rios JJ, Villamanan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers.
Pulm Circ. 2017; 7(3):692–701.
155. Sandoval J, Santos LE, Córdova J, Pulido T, Gutiérrez G, Bautista E et al. Does anticoagulation in
Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012; 7(3):268–276.
doi:10.1111/j.1747-0803.2012.00633.x.
156. Гончарова Н. С., Симакова М. А., Моисеева О. М. Антитромботическая терапия у пациентов с легочной артериальной гипертензией. Артериальная гипертензия. 2019; 25(1):25–33.
157. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996; 28(3):768–772.
158. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC,
Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van
Putte B, Vardas P; ESC Scientiﬁc Document Group. 2016 ESC Guidelines for the management of atrial ﬁbrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893–
2962.
159. Jentzer, J. C., Mathier, M. A. Pulmonary Hypertension in the Intensive Care Unit. Journal of
Intensive Care Medicine. 2015 31(6), 369–385.
160. Condliffe R, Kiely DG Critical care management of pulmonary hypertension. BJA Education.
2017; 17(7): 228–234.
161. Rhodes CJ, Wharton J, Howard L, Gibbs JS, Vonk-Noordegraaf A, Wilkins MR.
Iron deﬁciency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J.
2011; 38(6):1453–1460.
162. Rajdev A., Garan H., Biviano A. Arrhythmias in Pulmonary Arterial Hypertension// Prog
Cardiovasc Dis. 2012; 55(2): doi:10.1016/j.pcad.2012.06.002.
163. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2):76–81.
164. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension // Eur. Respir.
Rev. – 2009. – Vol. 18. – N. 111. – P. 29–34.
165. Opitz CF, Wensel R, Winkler J, et al. Clinical efﬁcacy and survival with ﬁrst-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart
J 2005; 26: 1895–1902.

166. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691–694.
167. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care
Med 2006; 174: 1257–1263.
168. Frost AE, the STEP investigators. STEP-open label extension: long-term beneﬁts of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am
J Respir Crit Care Med 2007; 175: Suppl., A1001.
169. Zheng Y, Yang T, Chen G, Hu E, Gu Q, Xiong C. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol. 2014; 70(1):13–21.
170. Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., Pollock J.S., Pollock D.M.,
Webb D.J., Maguire J.J. Endothelin. Pharmacol Rev. – 2016. – Vol. 68. – N. 2. – P. 357–418.
171. Miyagawa K., Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension // Ther. Adv. Cardiovasc. Dis. – 2014. – Vol. 8. –
N. 5. – P. 202–216.
172. Aversa M., Porter S., Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension // Drug Saf. – 2015. – Vol. 38. – N. 5. – P. 419–
435.
173. Galie´ N, Badesch BD, Oudiz R, Simonneau G, McGoon M, Keogh A, Frost A, Zwicke D, Naeije R,
Shapiro RS, Olschewski H, Rubin L. Ambrisentan therapy for pulmonary arterial hypertension. J
Am Coll Cardiol 2005; 46:529–535.
174. Galie´ N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD,
McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension randomized, doubleblind, placebo-controlled, multicenter, efﬁcacy (ARIES) study
1 and 2. Circulation 2008; 117:3010–3019.
175. McGoon M, Frost A, Oudiz R, Badesch BD, Galie` N, Olschewski H, McLaughlin VV, Gerber MJ,
Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122–129.
176. Belinda N. Rivera-Lebron and Michael G. Risbano Ambrisentan: a review of its use in pulmonary arterial hypertension Ther Adv Respir Dis 2017, Vol. 11(6) 233–244.
177. Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M,
Waterhouse B, Langley J, Galié N. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart Lung Transplant. 2017;
36(4):399–406.
178. Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, Anglen C, Kohan DE. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Am J
Cardiol. 2012; 110(9):1373–1377.
179.
Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S,
Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;
358:1119–1123.
180.
Humbert M, Barst RJ, Robbins IM, Channick RN, Galie` N, Boonstra A, Rubin LJ, Horn EM, Manes
A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353–359.
181.
Galie` N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A,
Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;
371:2093–2100.
182.
Galie` N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M.
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind,
randomized, placebo-controlled study. Circulation 2006; 114: 48–54.
183.
Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long term outcome with
ﬁrst line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2006;
27(5): 589–595.
184.
Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmcol Ther 2001; 69(4):223–231.
185.
McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenaﬁl therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405–413.

186.
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue- targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008; 327(3):736–745.
187.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun
FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X,
Rubin LJ, Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369(9): 809-818.
188.
Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T,
Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of Macitentan on Hospitalizations Results From the SERAPHIN Trial JACC: Heart Failure 2015; 3(1):1–8.
189.
Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L,
Krowka M. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.Lancet Respir Med.
2019; 7(7):594–604.
190.
Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova
S, Huppertz A, Klose H, Haefeli WE. Plasma Drug Concentrations in Patients with PAH on
Combination Treatment. Respiration 2017; 94(1):26–37.
191.
Chrysant S.G. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension // Curr. Hypertens. Rep. – 2013. – Vol. 15. – N. 5. –
P. 475–483.
192.
Galie` N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G,
Branzi A, Grimminger F, Kurzyna M, Simonneau G, the Sildenaﬁl Use in Pulmonary Arterial
Hypertension (SUPER) Study Group. Sildenaﬁl citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157.
193.
Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efﬁcacy of sildenaﬁl in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am
Coll Cardiol 2004; 43:1149–1153.
194.
Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenaﬁl in Eisenmenger syndrome: a randomized, placebo-controlled, double- blinded trial. Eur Heart J 2010; 31:1124–1131.
195.
Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebocontrolled,
double-blind, crossover study to evaluate the efﬁcacy of oral sildenaﬁl therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151:851.e1–851.e5.
196.
Мартынюк Т. В., Чазова И. Е. Роль силденафила в лечении пациентов легочной артериальной гипертензией. Системные гипертензии 2012; №2: с.23–29.
197.
Ghofrani H.A., Humbert M., Langleben D., Schermuly R., Stasch J.P., Wilkins M.R., Klinger J.R.
Riociguat: Mode of action and clinical development in pulmonary hypertension // Chest. –
2016. – Jun. 2. – pii: S0012–3692(16)49111–49117.
198.
Ghofrani H.A., Humbert M., Langleben D., Schermuly R., Stasch J.P., Wilkins M.R., Klinger J.R.
Riociguat: Mode of action and clinical development in pulmonary hypertension // Chest. –
2016. – Jun. 2. – pii: S0012–3692(16)49111–49117.
199.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D,
Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369(4): 330–340.
200.
Hossein-Ardeschir Ghofrani et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised,
long-term extension trial. Lancet Respir Med 2016; 4: 361–371.
201.
Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie` N, Degano B, Bonderman D,
Kurzyna M, Efﬁcace M, Giorgino R, Lang IM. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40:874–880.
202.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM,
Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G,
McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial
Hypertension. N Engl J Med. 2015; 373(26):2522–2533.
203.
Lang I, Gaine S, Galie N, et al. Effect of selexipag on long term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline:
results from the GRIPHON study [abstract 2365].Eur Heart J. 2015; 36(suppl 1):381–382.
204.
Fox B.D., Shtraichman O., Langleben D., Shimony A., Kramer M.R. Combination Therapy for
Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol. 2016
Dec; 32(12):1520–1530.
205.
Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S.
Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.

Lancet Respir Med. 2016; 4(4):291–305.
206.
Pan J, Lei L, Zhao C. Comparison between the efﬁcacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis Clin Exp Rheumatol. 2018; 36(6):1095–1102.
207.
Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock
AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group. Initial combination therapy with ambrisentan + tadalaﬁl on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant 2019; 38(2):194–202.
208.
Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM,
McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the
Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension
Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON
Study// Am J Cardiovasc Drugs.-2018.-Vol.18.-N1.-P.37–47.
209.
Sitbon O, Jaïs X, Savale L, Cottin V et al Upfront triple combination therapy in pulmonary arterial hypertension: a pilot studyю Eur Resp J 2014; 43: 1691–1697.
210.
Burks M, Stickel S, Galiè N. Pulmonary Arterial Hypertension: Combination Therapy in Practice.
Am J Cardiovasc Drugs. 2018; 18(4): 249–257.
211.
Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur
Respir J 2017; 50: 1602425.
212.
Politi MT, Caruson NA, Lescano J, et al. Switch from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension: a real-world study J Heart Lung Transplant. 2017;
36(4S):S166.
213.
Blok IM, van Riel ACMJ, van Dijk APJ et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol 2017;
227: 51–52.
214.
Kurzyna M., Dabrowski M., Bielecki D., Fijalkowska A., Pruszczyk P., Opolski G., Burakowski J.,
Florczyk M., Tomkowski W.Z., Wawrzynska L., Szturmowicz M., Torbicki A. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension // Chest. –
2007 – Vol. 131. – N. 4. – P. 977–983.
215.
Горбачевский С. В., Пурсанов М. Г., Шмальц А. А., Дадабаев Г. М.,Нишонов Н. А., Пардаев Д.
Б., Хачатурова И. Ю., Алекян Б. Г. Результаты атриосептостомии со стентированием у больных с идиопатической и схожими формами легочной артериальной гипертензии.
Грудная и сердечно-сосудистая хирургия 2019.-N 2.-С.100–113.
216.
Khan MS, Memon MM, Amin E, Yamani N, Khan SU, Figueredo VM, Deo S, Rich JD, Benza RL,
Krasuski
RA.
Use of
Balloon
Atrial
Septostomy in
Patients
With
Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Chest.
2019; 156(1):53–63.
217.
Bartolome S.D., Torres F. Severe pulmonary arterial hypertension: stratiﬁcation of medical therapies, mechanical support, and lung transplantation // Heart Fail Rev. – 2016 – Vol. 21. –
N. 3. – P. 347–356.
218.
Sonnweber T, Pizzini A, Tancevski I, Löfﬂer-Ragg J, Weiss G. Anaemia, Iron Homeostasis and
Pulmonary Hypertension: A Review. Intern Emerg Med. 2020 Feb 10. 2020 Feb 10. doi:
10.1007/s11739-020-02288-1.
219.
Jentzer J C, Mathier, M A. Pulmonary Hypertension in the Intensive Care Unit. J Intensive
Care Med. 2016; 31(6):369–385.
220.
Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53: 1801906.
221.
Gatzoulis M.A., Beghetti M., Landzberg M.J., Galiè N. Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions //
Int. J. Cardiol. – 2014. – Vol. 177. – N. 2. – P. 340–347.
222.
Diller G-P., Gatzoulis M. A. Pulmonary Vascular Disease in Adults With CHD
//Circulation.-2007.-Vol.115.-N8.-P.1039-1050.
223.
Lopes AA, O"Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009;
19(5):431–435.
224.
Bruch L, Winkelmann A, Sonntag S, Scherf F, Rux S, Grad MO, Kleber FX. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure.
J Interv Cardiol. 2008 Feb; 21(1):44–49.
225.
Kretschmar O, Sglimbea A, Corti R, Knirsch W. Shunt reduction with a fenestrated Amplatzer device. Catheter Cardiovasc Interv. 2010; 76(4):564–571.

226.
Janjua AM, Saleem K, Khan I, et al. Double ﬂap patch closure of VSD with elevated pulmonary vascular resistance: an experience at AFIC/NIHD. J Coll Physicians Surg Pak. 2011; 21(4):197–
201.
227.
Talwar S, Keshri VK, Choudhary SK, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac
Cardiovasc Surg. 2014; 148(6):2570–2575.
228.
Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M;
BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol.
2008; 127(1):27–32.
229.
Gatzoulis M.A. Landzberg M., Beghetti M. Berger R.M. et al. Evaluation of Macitentan in
Patients with Eisenmenger Syndrome: Results from the Randomized, Controlled MAESTRO
Study//Circulation.- 2019.- Vol.139.-N1.-P.51–63.
230.
Cavagna L., Codullo V., Ghio S., Scire C.A., Guzzafame E., Scelsi L., Rossi S., Montecucco C.,
Caporali R. Undiagnosed connective tissue diseases. High prevalence in pulmonary arterial hypertension patients. Medicine. 2016. 95:39(e4827).
231.
Ahmed S, Palevsky H. Pulmonary Arterial Hypertension Related to Connective Tissue Disease: A
Review.Rheum Dis Clin North Am. 2014; 40(1):103–124.
232.
Le Pavec J, Humbert M, Mouthon L. Systemic Sclerosis-associated Pulmonary Arterial
Hypertension. Am J Respir Crit Care Med. 2010; 181(12):1285–1293.
233.
Cottin V. Pulmonary arterial hypertension in connective tissue disease. Rev Mal Respir 2006;
23:13S61–72.
234.
Hachulla E, Carpentier P, Gressin V. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology. 2009;
48(3):304–308.
235.
Hinchcliff M, Fischer A, Schiopu E, et al. Pulmonary Hypertension Assessment and
Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172–2179.
236.
Young, A., Vummidi, D., Visovatti, S., Homer, K., Wilhalme, H., White, E. S., Khanna, D.
Prevalence, Treatment and Outcomes of Coexistent Pulmonary Hypertension and Interstitial
Lung Disease in Systemic Sclerosis. Arthritis & Rheumatology. 2019 doi:10.1002/art.40862.
237.
Hsu VM, Chung L, Hummers LK. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014; 44(1):55–62.
238.
Gupta S, Gupta A, Rehman S, Ocak I, Domsic RT, Schneider F, George MP Pulmonary veno- occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation
ERJ Open Research 2019 5: 00168–2018.
239.
Chung L., Liu J., Parsons L., Hassoun P.M., McGoon M., Badesch D.B., Miller D.P., Nicolls M.R.,
Zamanian R.T. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype// Chest. –
2010. – Vol. 138. – N.6. – p. 1383–1394.
240.
Coghlan J.G., Denton C.P., Grünig E., Bonderman D., Distler O., Khanna D., Müller-Ladner U.,
Pope J.E., Vonk M.C., Doelberg M., Chadha-Boreham H., Heinzl H., Rosenberg D.M.,
McLaughlin V.V., Seibold J.R; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study // Ann Rheum.
Dis. – 2014. – Jul. – Vol. 73. – N. 7. – P. 1340–1349.
241.
Волков А. В., Мартынюк Т. В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани: современное состояние проблемы. Научно- практическая ревматология. 2018; 56(4):474–485.
242.
Coghlan, J., Denton, C. P. Aggressive combination therapy for treatment of systemic sclerosis- associated pulmonary hypertension. Journal of Scleroderma and Related Disorders, 2018; 3(1),
30–38.
243.
Gunther S, Jaïs X, Maitre S, et al. Computed tomography ﬁndings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis
Rheumatol. 2012; 64:2995–3005.
244.
Matthew R. Lammi, Stephen C. Mathai, Lesley Ann Saketkoo, Robyn T. Domsic, Christine
Bojanowski, Daniel Furst, Virginia Steen, for the PHAROS Investigators. Association between
Initial Oral Therapy and Outcomes in Systemic Sclerosis-related Pulmonary Arterial
Hypertension: Observations from PHAROS Arthritis Rheumatol. 2016; 68(3): 740–748.
245.
Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV,
Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin

LJ; AMBITION investigators. Initial combination therapy with ambrisentan and tadalaﬁl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial// Ann Rheum Dis.-2017.-Vol. 76.-N7.-P.1219–1227.
246.
Humbert M, Coghlan JG, Ghofrani H-A, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from
PATENT-1 and PATENT-2. Ann Rheum Dis. 2017; 76(2):422–426.
247.
Krowka M.J., Fallon M.B., Kawut S.M., Fuhrmann V., Heimbach J.K., Ramsay M.A., Sitbon O.,
Sokol R.J. International Liver Transplant Society Practice Guidelines: Diagnosis and
Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension //
Transplantation. – 2016. – Vol. 100. – N. 7. – P. 1440–1452.
248.
Sithamparanathan
S,
Nair
A,
Thirugnanasothy
L,
Coghlan
JG, et al.
Survival in portopulmonary hypertension: Outcomes of the United Kingdom National
Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017; 36(7):770–779.
249.
Gough MS, White RJ. Sildenaﬁl therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009; 15:30–36.
250.
Correale M., Palmiotti G.A., Lo Storto M.M., Montrone D., Foschino Barbaro M.P., Di Biase M.,
Lacedonia D. HIV-associated pulmonary arterial hypertension: from bedside to the future // Eur.
J. Clin. Invest. – 2015. – Vol. 45 – N. 5 – P. 515–528.
251.
Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 2011; 12:103.
252.
Spikes L, Dalvi P, Tawﬁk O, et al. Enhanced pulmonary arteriopathy in simian immunodeﬁciency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med 2012; 185:1235–1243.
253.
Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension:
survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24:67–75.
254.
Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142:448–456.
255.
Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med
2003; 167:1433–1439.
256.
Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of
HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA
Panel. JAMA 2016; 316:191–210.
257.
Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res 2009; 7:589–596.
258.
Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenaﬁl and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50:99–107.
259.
Barnett CF, Machado RF. Sildenaﬁl in the treatment of pulmonary hypertension. Vasc Health
Risk Manag 2006; 2:411–22.
260.
Chinello P, Petrosillo N. Pharmacological treatment of HIV-associated pulmonary hypertension.
Expert Review of Clinical Pharmacology, 2016, 9:5, 715–725.
261.
Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J. 2004; 23:321–326.
262.
Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Äänismaa P, Halabi A, Dingemanse J. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects Br J Clin Pharmacol. 2015; 80(4): 670–677.
263.
Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 170:1212–
1217.
264.
Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with
HIVassociated pulmonary arterial hypertension. Eur Respir J. 2009; 33:92–98.
265.
Montani D., Lau E.M., Dorfmüller P., Girerd B., Jaïs X., Savale L., Perros F., Nossent E., Garcia G.,
Parent F., Fadel E., Soubrier F., Sitbon O., Simonneau G., Humbert M. Pulmonary veno-occlusive disease // Eur. Respir. J. – 2016. – Vol. 47 – N. 5. – P. 1518–1534.
266.
McLaughlin V.V., Shah S.J., Souza R., Humbert M. Management of pulmonary arterial hypertension // J. Am. Coll. Cardiol. – 2015. – Vol. 65. – P. 18. – P. 1976–1997; Rosenkranz S.,
Gibbs J.S., Wachter R., De Marco T., Vonk-Noordegraaf A., Vachiéry J.L. Left ventricular heart failure and pulmonary hypertension // Eur. Heart. J. – 2016. – Vol. 37 – N. 12. – P. 942–954.
267.
Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, Coghlan G, Chazova I, De
Marco T. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019; 53(1). pii:
1801897.

268.
Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;
124 (2): 164–174.
269.
Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo- controlled, dose-ranging hemodynamic study. Circulation 2013; 128(5): 502–511.
270.
Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51(2): 1701886.
271.
Bermejo J, Yotti R, García-Orta R, et al. Sildenaﬁl for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double- blind, randomized clinical trial. Eur Heart J 2018; 39(15): 1255–1264.
272.
Skoro-Sajer N, Marta G, Gerges C, Hlavin G, Nierlich P, Taghavi S, Sadushi-Kolici R, Klepetko W,
Lang IM. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy// Thorax. - 2014.-Vol.69.-N.2-P.116–122.
273.
Jenkins D, Madani M, Fadel E, D"Armini AM, Mayer E. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;
26(143): pii: 160111.
274.
Jenkins DP, Biederman A, D"Armini AM, Dartevelle PG, Gan HL, Klepetko W, Lindner J, Mayer
E, Madani MM. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac
Cardiovasc Surg. 2016; 152(3):669–674.
275.
Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev. 2017; 26(146). pii: 170105.
276.
Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon Pulmonary Angioplasty
(Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic
Pulmonary Hypertension: A Japanese Perspective. JACC Cardiovasc Interv. 2019; 12(14):1382–
1388.
277.
Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G,
Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension// N Engl J Med.- 2013 Vol.369.-N4.-P.319–329.
278.
Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, Tatebe S, Miyamichi-Yamamoto
S, Shimokawa H. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-termprognosis in patients with chronic thromboembolic pulmonary hypertension// Circ J.- 2012.-Vol.76.-N2.-P.485–488.
279.
Sliwa K, van Hagen IM, Budts W, et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of
Cardiology. Eur J Heart Fail. 2016; 18 (9): 1119–28.
280.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165–3241.
281.
Makino Y, Matsuda Y, Mitani M, et al. Risk factors associated with preterm delivery in women with cardiac disease. J Cardiol 2012; 59: 291–298.
282.
Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018.
Национальные рекомендации. Российский кардиологический журнал 2018, 3 (155): 91–
134.
283.
Pijuan-Domenech A, Galian L, Goya M, Casellas M, Merced C, Ferreira-Gonzalez I, Marsal-Mora
JR, Dos-Subira L, Subirana-Domenech MT, Pedrosa V, Baro-Marine F, Manrique S, Casaldaliga-
Ferrer J, Tornos P, Cabero L, Garcia-Dorado D. Cardiac complications during pregnancy are better predicted with the modiﬁed who risk score. Int J Cardiol 2015; 195:149–154.
284.
Vigl M, Kaemmerer M, Niggemeyer E, Nagdyman N, Seifert-Klauss V, Trigas V, Bauer U,
Schneider KT, Berger F, Hess J, Kaemmerer H. Sexuality and reproductive health in women with congenital heart disease. Am J Cardiol 2010; 105:538–541.
285.
Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30:256–265.
286.
Roos-Hesselink JW, Budts W, Walker F, De Backer JFA, Swan L, Stones W, Kranke P, Sliwa-Hahnle
K, Johnson MR. Organisation of care for pregnancy in patients with congenital heart disease.
Heart 2017; 103:1854–1859.
287.
Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;
25: с.431–437.
288.
Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin
Respir Crit Care Med 2013; 34: с.681–688.
289.
Hsu CH, Gomberg-Maitland M, Glassner C, et al. The management of pregnancy and pregnancy- related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl

2011; 175: 6–14.
290.
Chandrasekhar S, Cook CR, Collard CD. Cardiac surgery in the parturient. Anesth Analg. 2009;
108: 777–785.
291.
Ireland LD, Gatter M, Chen AY. Medical compared with surgical abortion for effective pregnancy termination in the ﬁrst trimester. Obstet Gynecol 2015; 126:22–28.
292.
Hemnes A.R., Kiely D.G., Cockrill B.A. et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ 2015; 5: 435–465.
293.
Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 2016; 316:952–961.
294.
Kelaranta A, Kaasalainen T, Seuri R, Toroi P, Kortesniemi M. Fetal radiation dose in computed tomography. Radiat Prot Dosimetry 2015; 165:226–230.
295.
Jais X, Olsson KM, Barbera JA, et al. Pregnansy outcomes in pulmonary arterial hypertension in the modern management era. EurRespir J 2012; 40: 881–885.
296.
Treinen KA, Louden C, Dennis MJ, et al. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 1999; 59: с.51–59.
297.
Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. 2015
RCOG Green-top Guideline No. 37a
298.
Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efﬁcacy.
Blood 2005; 106:401–407.
299.
Terek D, Kayikcioglu M, Kultursay H, et al. Pulmonary arterial hypertension and pregnancy. J Res
Med Sci 2013; 18: с.73–76.
300.
Madden BP. Pulmonary hypertension and pregnancy. Int J Obstet Anesth 2009; 18: 156–164.
301.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M et al. Deﬁnitions and
Diagnosis of Pulmonary Hypertension. J Am Coll Cardiology 2013; 24;62(25 Suppl): D42–50.
302.
Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013; 143:1330–1336.
303.
Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102:
с.1133–1137.
304.
Баутин А. Е., Якубов А. В., Коконина Ю. А., Ильин А. Б., Ли О. А., Иртюга О. Б., Мазурок В. А.,
Зазерская И. Е., Моисеева О. М. Анестезиологическое обеспечение и интенсивная терапия в периоперационном периоде абдоминального родоразрешения у беременных с легочной артериальной гипертензией. Анестезиология и реаниматология 2016; №6: 455–461.
305.
Hill W., Holy R., Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in
Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ.
2018 Jun 12.
306.
Thorne S, Nelson-Piercy C, MacGregor AJ, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam PlannReprod Health Care 2006; 32:75–81.
307.
Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257–2266.
308.
Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009; 339:b2890.
309.
Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345: e4944.
310.
Vieira CS, Ferriani RA, Garcia AA, Pintao MC, Azevedo GD, Gomes MK, Silvade-Sa MF. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Hum Reprod 2007; 22:2196–2201.
311.
Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J 2015; 36:1728–1734.
312.
Cheng L, Che Y, Gulmezoglu AM. Interventions for emergency contraception. Cochrane
Database Syst Rev 2012; 8:CD001324.
313.
Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59:79–83.
314.
Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013;
29:1–14.
315.
Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, Brache V. A
prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception 2016; 93:310–316.
316.
Nickel N, Golpon H, Greer M et. Al The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39:589–596.

317.
Barst RJ, Chung L, Zamanian RT et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013;
144:160–168.
318.
Bustamante-Labarta M, Perrone S, De La Fuente RL, Stutzbach P, De La Hoz RP, Torino A,
Favaloro R. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 2002; 15:1160–
1164.
319.
Forﬁa PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti
MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174:1034–1041.
320.
Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr 2010; 23: 943–953.
321.
Smith BC, Dobson G, Dawson D, Charalampopoulos A, Grapsa J, Nihoyannopoulos P. Three- dimensional speckle tracking of the right ventricle: toward optimal quantiﬁcation of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 2014; 64:41–51.
322.
Grünig E, Peacock AJ. Imaging the heart in pulmonary hypertension: an update. Eur Respir Rev.
2015;24(138):653-64. Wright LM, Dwyer N, Celermajer D, Kritharides L, Marwick TH. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging. 2016; 9(6):733–
746.
323.
Wright LM, Dwyer N, Celermajer D, Kritharides L, Marwick TH. Follow-Up of Pulmonary
Hypertension With Echocardiography. JACC Cardiovasc Imaging. 2016; 9(6):733–746.
324.
Raymond R.J., Hinderliter A.L., Willis P.W., Ralph D., Caldwell E.J., Williams W., Ettinger N.A.,
Hill N.S., Summer W.R., de Boisblanc B., Schwartz T., Koch G., Clayton L.M., Jöbsis M.M., Crow
J.W., Long W. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39(7):1214–1219.
325.
Sachdev A., Villarraga H.R., Frantz R.P., McGoon M.D., Hsiao J.F., Maalouf J.F., Ammash N.M.,
McCully R.B., Miller F.A., Pellikka P.A., Oh J.K., Kane G.C. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011; 139(6):1299–1309.
326.
Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev. 2013; 22(130):526–534.
327.
Baggen VJ, Leiner T, Post MC, van Dijk AP, Roos-Hesselink JW, Boersma E, Habets J, Sieswerda
GT. Cardiac magnetic resonance ﬁndings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Radiol. 2016; 26(11):3771–
3780.
328.
Kang K., Chang H., Kim Y., Choi B., Lee H., Yang W., et al. Cardiac magnetic resonance imaging- derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension. Circ J. 2011; 75:
2244–2251 329. van Wolferen SA, Marcus JT, Boonstra A, Marques KMJ, Bronzwaer JGF, Spreeuwenberg MD,
Postmus PE, Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hyperten-sion. Eur Heart J 2007; 28:1250–1257.
330.
Swift AJ, Rajaram S, Campbell MJ, Hurdman J, Thomas S, Capener D, Elliot C, Condliffe R, Wild
JM, Kiely DG. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc
Imaging 2014; 7:100–106.
331.
Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant
2015; 34(3): 362–368.
332.
Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenﬁre M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur
Respir J 2001; 17:647–652.
333.
Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R,
Ewert R. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106:319–324.
334.
Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, Winkler J, Seyfarth HJ, Glaser S,
Blumberg F, Obst A, Dandel M, Hetzer R, Ewert R. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013; 167:1193–1198.106.
335.
Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, WenselR. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail

2013; 15:771–775.
336.
Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B,
Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005;
112:828–835.
337.
Arena R, Lavie CJ, Milani RV, Myers J, Guazzi M. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant 2010;
29:159–173.
338.
Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L,
Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich
S, Vizza D, Vonk Noordegraaf A, Olschewski H. An ofﬁcial European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017 Nov 22; 50(5).
339.
Groepenhoff H., Vonk-Noordegraaf A., van de Veerdonk M.C., Boonstra A., Westerhof N.,
Bogaard H.J. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013; 8(9):e72013.
340.
Anwar A, Ruffenach G, Mahajan A, Eghbali M, Umar S. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016; 17(1):88.
341.
Rosenthal JL, Jacob MS. Biomarkers in pulmonary arterial hypertension.Curr Heart Fail Rep.
2014 Dec; 11(4):477–484.
342.
Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, Muehling O,
Behr J. N-terminal pro-brain natriuretic peptide and renal insufﬁciency as predictors of mortality in pulmonary hypertension. Chest. 2007; 131(2):402–409.
343.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur J Heart Fail. 2016; 18(8):891–
975.
344.
Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte
H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo- controlled phase 2b study. Lancet Respir Med. 2019; 7(9):780–790.
345. Юдкина Н. Н., Николаева Е. В., Мартынюк Т. В., Волков А. В. Клинический субтип системной склеродермии, ассоциированный с легочной артериальной гипертензией.
Кардиологический вестник. Том XII. №4. С. 66–75.
346. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF,
Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M,
Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax
JJ;
ESC
Scientiﬁc
Document
Group.
2019
ESC
Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019 Aug 31. pii:
ehz425.
347. Казымлы А.В., Рыжков А.В., Симакова М.А. и др. Значение двухмерной эхокардиографии в оценке степени тяжести пациентов с легочной гипертензией Кардиология. 2016. Т. 56. No
1. С. 25-30.
348. Daliento L., Somerville J., Presbitero P. et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998; 19(12):1845–1855.
349. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2006; 27:114–
120.

1 ... 9 10 11 12 13 14 15 16 17